Delphine Diagnostics Receives Maternal and Infant Health R & D Award Grant from the New Jersey Commission on Science Innovation and Technology (NJ CSIT)

Princeton, NJ. March 5, 2025

New Jersey – Delphine Diagnostics, a pioneering company in medical diagnostics, is honored to announce that it has been awarded the Maternal and Infant Health Award on Tuesday, March 5, 2025. This recognition highlights the company’s dedication to developing faster and more accurate diagnostic solutions to improve healthcare outcomes for pregnant women and infants.

The Delphine Diagnostics team extends its deepest gratitude to First Lady Tammy Murphy, NJEDA CEO Tim Sullivan, MIHIA Chair Lisa Asare, and CSIT Executive Director Judith Sheft for their support and for championing advancements in maternal and infant health.

“At Delphine Diagnostics, we are committed to revolutionizing medical diagnostics to provide safer, more joyful, and sacred experiences for expecting mothers and infants,” said Andy Bala, CEO at Delphine Diagnostics. “This award reinforces our mission to improve early detection and patient outcomes through cutting-edge technology.”

With a team of industry experts and healthcare innovators, Delphine Diagnostics continues to develop next-generation diagnostic tools aimed at enhancing maternal healthcare and addressing critical challenges in perinatal care.

For more information about the CSIT Award, please click here.